DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-15.04%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$1.45B
AUM Growth
+$1.45B
(-6.6%)
Cap. Flow
+$232M
Cap. Flow
% of AUM
16.05%
Top 10 Holdings %
Top 10 Hldgs %
49.78%
Holding
57
New
6
Increased
22
Reduced
11
Closed
6
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$54.2M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$42.9M |
| 3 |
Nuvation Bio
NUVB
|
$33.4M |
| 4 |
Nurix Therapeutics
NRIX
|
$30.9M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$24.4M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$75.7M |
| 2 |
Keros Therapeutics
KROS
|
$17.7M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$16.3M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
$14.1M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$9.25M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AUTL
51
Autolus Therapeutics
AUTL
$399M
| – | – |
-382,559
| Closed | -$1.6M |
|
|
52
Enanta Pharmaceuticals
ENTA
$180M
| – | – |
-198,730
| Closed | -$14.1M |
|
53
Nektar Therapeutics
NKTR
$568M
| – | – |
0
| – | – |
|
54
Protagonist Therapeutics
PTGX
$3.67B
| – | – |
0
| – | – |
|
55
Rafael Holdings
RFL
$51.6M
| – | – |
-104,156
| Closed | -$261K |
|
|
VERV
56
DELISTED
Verve Therapeutics
VERV
| – | – |
-102,342
| Closed | -$2.34M |
|
|
RXDX
57
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-245,000
| Closed | -$9.25M |
|